Genetically engineered T cells as adoptive immunotherapy of cancer.
Ma
Qiangzhong
Q
Biotherapeutics Development Lab, Harvard Institute of Human Genetics, Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Gonzalo-Daganzo
Rosa M
RM
Junghans
Richard P
RP
D000818:Animals; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000378:metabolism; D005818:Genetic Engineering; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D016246:Lymphocytes, Tumor-Infiltrating / Q000378:metabolism / Q000637:transplantation*; D051379:Mice; D009369:Neoplasms / Q000378:metabolism / Q000628:therapy*; D016176:T-Lymphocyte Subsets / Q000637:transplantation*
D016207:Cytokines